DrugPatentWatch Database Preview
NASONEX Drug Profile
Which patents cover Nasonex, and when can generic versions of Nasonex launch?
Nasonex is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has forty-six patent family members in thirty-three countries.
The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for NASONEX
International Patents: | 46 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Bulk Api Vendors: | 58 |
Clinical Trials: | 45 |
Patent Applications: | 4,164 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NASONEX |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NASONEX |
DailyMed Link: | NASONEX at DailyMed |

Pharmacology for NASONEX
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for NASONEX
Synonyms for NASONEX
(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione |
(1R,2S,10S,11S,13R,14R,15S,17S)-1-CHLORO-14-(2-CHLOROACETYL)-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE |
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate |
(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate |
04201GDN4R |
11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate |
2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester |
83919-23-7 |
9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate |
9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) |
919M237 |
A840685 |
AB2000407 |
AC-941 |
AC1L9AZS |
AK163902 |
AKOS015994732 |
AN-15438 |
Asmanex |
Asmanex HFA |
Asmanex Twisthaler |
BC228151 |
BDBM50148733 |
BPBio1_000424 |
BRD-K60640630-001-03-7 |
BRN 4340538 |
BSPBio_000384 |
C07817 |
C27H30Cl2O6 |
CAS-83919-23-7 |
CCG-220572 |
CHEBI:47564 |
CHEMBL1161 |
CS-2389 |
D00690 |
Danitin |
DR003147 |
DSSTox_CID_3333 |
DSSTox_GSID_23333 |
DSSTox_RID_76981 |
DTXSID4023333 |
Ecural |
Elocon |
Elocone |
Elomet |
Flumeta |
HMS1569D06 |
HMS2096D06 |
HMS2235I14 |
HY-13693 |
KS-00000SPL |
KS-1275 |
LAS 41002 |
M2354 |
MLS002153879 |
MolPort-003-849-257 |
Mometasone 17-(2-furoate) |
mometasone 17-furoate |
mometasone furancarboxylate |
mometasone furoate |
Mometasone furoate (JAN/USP) |
Mometasone furoate [USAN:USP:JAN] |
Mometasone furoate hydrate |
Mometasone Furoate Impurity G |
MOMETASONE FUROATE MONOHYDRATE |
Mometasone furoate, >=98% (HPLC) |
Mometasone furoate, European Pharmacopoeia (EP) Reference Standard |
Mometasone Furoate, pharmaceutical secondary standard; traceable to USP, PhEur and BP |
Mometasone furoate, United States Pharmacopeia (USP) Reference Standard |
Monovo |
NCGC00016950-01 |
NCGC00179578-01 |
NCGC00179578-03 |
NCGC00179578-04 |
Nosorex |
NSC-746171 |
NSC746171 |
Ovixan |
PL071566 |
Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)- |
Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)- |
Prestwick_924 |
Prestwick0_000572 |
Prestwick1_000572 |
Prestwick2_000572 |
Prestwick3_000572 |
Q-101380 |
Rimelon |
s1987 |
Sch 32088 |
Sch-32088 |
SCHEMBL4568 |
Sinuva |
SMR001233233 |
SPBio_002603 |
SR-01000841209 |
SR-01000841209-2 |
ST24048112 |
TL8005500 |
Tox21_110705 |
Tox21_110705_1 |
UNII-04201GDN4R |
WOFMFGQZHJDGCX-ZULDAHANSA-N |
ZINC3938677 |
US Patents and Regulatory Information for NASONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for NASONEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Merck Sharp Dohme | NASONEX | mometasone furoate | SPRAY, METERED;NASAL | 020762-001 | Oct 1, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for NASONEX
Drugname | Dosage | Strength | RLD | Date |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 50 mcg/ Spray | ➤ Subscribe | ➤ Try a Free Trial |
International Patents for NASONEX
Country | Document Number | Estimated Expiration |
---|---|---|
Estonia | 02962 | ➤ Try a Free Trial |
South Africa | 9107148 | ➤ Try a Free Trial |
Australia | 663471 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for NASONEX
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
875032 | Germany | ➤ Try a Free Trial | PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219 |
5/1998 | Austria | ➤ Try a Free Trial | PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT |
C/GB97/064 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |